Published on 6/11/2015 in the Prospect News Structured Products Daily.
New Issue: JPMorgan prices $3.26 million capped return enhanced notes on S&P 500
By Susanna Moon
Chicago, June 11 – JPMorgan Chase & Co. priced $3.26 million of capped enhanced notes due June 14, 2017 linked to a basket of eight equally weighted stocks, according to a 424B2 filing with the Securities and Exchange Commission.
The underlying stocks are Vertex Pharmaceuticals Inc., Regeneron Pharmaceuticals, Inc., Puma Biotechnology, Inc., Intercept Pharmaceuticals, Inc., Horizon Pharma plc, Esperion Therapeutics, Inc., BioMarin Pharmaceutical Inc. and Biogen Idec Inc.
The payout at maturity will be par plus triple any basket gain, up to a maximum return of 38.25%.
Investors will be exposed to any losses.
J.P. Morgan Securities LLC is the agent.
| Issuer: | JPMorgan Chase & Co.
|
| Issue: | Capped return enhanced notes
|
| Underlying basket: | Vertex Pharmaceuticals Inc., Regeneron Pharmaceuticals, Inc., Puma Biotechnology, Inc., Intercept Pharmaceuticals, Inc., Horizon Pharma plc, Esperion Therapeutics, Inc., BioMarin Pharmaceutical Inc. and Biogen Idec Inc., equally weighted
|
| Amount: | $3,255,000
|
| Maturity: | June 14, 2017
|
| Coupon: | 0%
|
| Price: | Par
|
| Payout at maturity: | Par plus 3 times any basket gain, capped at 38.25%; exposure to any losses
|
| Pricing date: | June 9
|
| Settlement date: | June 12
|
| Agent: | J.P. Morgan Securities LLC
|
| Fees: | 2.4%
|
| Cusip: | 48125UWH1
|
|
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
